Literature DB >> 15830012

Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.

E Mejstríková, T Kalina, J Trka, J Starý, O Hrusák.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15830012     DOI： 10.1038/sj.leu.2403737

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.

Authors:  Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimir Mihal; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Zdenka Cerna; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

2.  Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.

Authors:  Ester Mejstrikova; Jana Volejnikova; Eva Fronkova; Katerina Zdrahalova; Tomas Kalina; Jaroslav Sterba; Yahia Jabali; Vladimir Mihal; Bohumir Blazek; Zdena Cerna; Daniela Prochazkova; Jiri Hak; Zuzana Zemanova; Marie Jarosova; Alexandra Oltova; Petr Sedlacek; Jiri Schwarz; Jan Zuna; Jan Trka; Jan Stary; Ondrej Hrusak
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

3.  A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.

Authors:  Ingo Schubert; Christian Kellner; Christoph Stein; Markus Kügler; Michael Schwenkert; Domenica Saul; Kristin Mentz; Heiko Singer; Bernhard Stockmeyer; Wolfgang Hillen; Andreas Mackensen; Georg H Fey
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 4.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

5.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

Review 6.  The intriguing roles of Siglec family members in the tumor microenvironment.

Authors:  Kui-Ying Jiang; Li-Li Qi; Fu-Biao Kang; Ling Wang
Journal:  Biomark Res       Date:  2022-04-13

7.  Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.

Authors:  Tomas Kalina; Martina Vaskova; Ester Mejstrikova; Jozef Madzo; Jan Trka; Jan Stary; Ondrej Hrusak
Journal:  BMC Cancer       Date:  2005-04-12       Impact factor: 4.430

Review 8.  Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.

Authors:  Dowdy Jackson; David Stover
Journal:  Pharm Res       Date:  2014-10-23       Impact factor: 4.200

9.  Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.

Authors:  Claudia C Roskopf; Todd A Braciak; Nadja C Fenn; Sebastian Kobold; Georg H Fey; Karl-Peter Hopfner; Fuat S Oduncu
Journal:  Oncotarget       Date:  2016-04-19

10.  CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.

Authors:  Jana Reimer; Sabine Knöß; Maurice Labuhn; Emmanuelle M Charpentier; Gudrun Göhring; Brigitte Schlegelberger; Jan-Henning Klusmann; Dirk Heckl
Journal:  Haematologica       Date:  2017-06-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.